Sanofi India Q2 CY2026 Investor Presentation: Diabetes Business Drives 8% Revenue Growth

What Happened ?

During the Q2 CY2026 Investor Presentation, management highlighted continued execution of its diabetes growth strategy through innovation, wider public healthcare penetration and strengthened partnerships.

The company emphasized that its innovative diabetes portfolio—including Toujeo and Soliqua—continued gaining traction, while investments in scientific evidence, AI-enabled patient support and digital outreach are expected to support long-term growth. 

key details

Strong Domestic Business Performance:

• Domestic revenue increased 8% YoY to ₹3,559 million.
• Diabetes remained the largest contributor to domestic sales.
• Insulin business generated ₹2,031 million.
• Partnership business contributed ₹1,457 million.
• Continued resource optimisation supported profitability.

Note:

• Management attributed growth primarily to strong performance in the Diabetes franchise and expanding partnership business. 

Diabetes Franchise Continues to Lead Growth:

• Diabetes business continued growing above market growth.
• Innovative diabetes portfolio recorded double-digit growth.
• Public sector business expanded 70% through new Toujeo and Soliqua accounts.
• Digital outreach expanded across Tier-II and Tier-III cities.
• Partnerships continued delivering higher return on investment.

Note:

• Management identified diabetes as the company’s primary long-term growth engine in India. 

Innovation & Market Leadership:

• Toujeo and Soliqua continued strengthening market positioning.
• LANDMARC Real World Evidence (RWE) study expanded scientific evidence.
• Additional RWE publications supported physician engagement.
• AI-enabled patient support platforms are under preparation.
• Novel delivery device initiatives remain under development.

Note:

• Management continues investing in evidence-based medicine and digital patient engagement to strengthen long-term market leadership. 

Diabetes Market Position:

• Basal insulin market leader with 47% market share by value.
• Basal analog market share:
  • 58% by value
  • 61% by volume
• Preferred second-generation basal insulin continued expanding market presence.
• Volume growth reached 6%.

Note:

• Sanofi remains one of India’s leading insulin manufacturers, supported by its strong diabetes portfolio. 

CSR & Community Healthcare:

The company highlighted progress across healthcare initiatives:

• Kids and Diabetes in Schools (KiDS) programme expanded to:
  • 80,000+ students
  • 400+ schools
  • 450+ teachers
• Mobile Medical Units reached:
  • 80,000+ patients treated
  • 71,000+ diagnosed
  • 64,000+ screened
• More than 600,000 direct beneficiaries reached through CSR programmes.

Note:

• Community healthcare initiatives remain an integral part of Sanofi India’s long-term sustainability strategy. 

Risk Analysis

Summary:

• While Sanofi India’s Diabetes business continues delivering healthy growth, future performance depends on sustaining innovation, public-sector expansion, competitive positioning and regulatory developments within the pharmaceutical industry.

Key Risks:

• Increased competition in the insulin market.
• Pricing and reimbursement pressures.
• Regulatory changes affecting pharmaceutical products.
• Slower public-sector procurement.
• Dependence on continued diabetes portfolio growth.
• Supply-chain disruptions affecting product availability.

Worst Case:

• If competitive pricing intensifies or public-sector procurement slows, growth in the Diabetes franchise could moderate despite continued investments in innovation and market expansion.

Risk Level: Medium

Conclusion

• Diabetes remains the primary growth driver.
• Public-sector expansion continues to gain momentum.
• Toujeo and Soliqua remain strategic products.
• AI-enabled patient support initiatives are under development.
• Scientific evidence generation continues strengthening physician engagement.
• Long-term focus remains on innovation, patient care and sustainable growth.